Clovis
Showing 101 - 125 of 139
NSCLC Trial in Worldwide (Rociletinib)
Terminated
- Non-small Cell Lung Cancer
-
Alhambra, California
- +90 more
Jul 28, 2020
Breast Ductal Carcinoma In Situ Trial in Worldwide (other, biological, radiation)
Active, not recruiting
- Breast Ductal Carcinoma In Situ
- Laboratory Biomarker Analysis
- +2 more
-
Anniston, Alabama
- +1267 more
Jan 28, 2023
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7 Trial in Worldwide (drug, other, radiation)
Active, not recruiting
- Breast Adenocarcinoma
- +6 more
- Anastrozole
- +6 more
-
Anniston, Alabama
- +1230 more
Jan 28, 2023
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell
Active, not recruiting
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7
- +3 more
- Bevacizumab
- +7 more
-
Anniston, Alabama
- +1174 more
Jan 28, 2023
Lung Cancer Trial in Worldwide (Standard Radiation Dose Therapy, cisplatin, etoposide)
Active, not recruiting
- Lung Cancer
- Standard Radiation Dose Therapy
- +4 more
-
Birmingham, Alabama
- +933 more
Jan 8, 2021
Lung Adenocarcinoma, Lung Large Cell Carcinoma, Resectable Lung Non-Small Cell Carcinoma Trial in Guam, Puerto Rico, United
Recruiting
- Lung Adenocarcinoma
- +12 more
- Carboplatin
- +12 more
-
Birmingham, Alabama
- +1612 more
Aug 23, 2022
Colorectal Tumors Trial in United States (Eflornithine & sulindac , eflornithine & sulindac , Eflornithine & sulindac)
Recruiting
- Colorectal Neoplasms
- Eflornithine placebo & sulindac placebo
- +3 more
-
Birmingham, Alabama
- +985 more
Aug 23, 2022
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial in Worldwide (Rucaparib)
Completed
- Ovarian Cancer
- +3 more
-
San Francisco, California
- +15 more
Jan 19, 2021
Coronary Artery Disease Trial in United States (Percutaneous Coronary Intervention)
Completed
- Coronary Artery Disease
- Percutaneous Coronary Intervention
-
Clovis, California
- +5 more
May 24, 2017
Locally Advanced or Metastatic Non Small Cell Lung Cancer Trial in Worldwide (Rociletinib)
Terminated
- Locally Advanced or Metastatic Non Small Cell Lung Cancer
-
Duarte, California
- +48 more
Jul 26, 2020
NSCLC Trial in United States (Rociletinib, Trametinib)
Terminated
- Non-small Cell Lung Cancer
-
Saint Louis, Missouri
- +3 more
Sep 28, 2018
NSCLC Trial in United States (Rociletinib)
No longer available
- Non-small Cell Lung Cancer
-
Scottsdale, Arizona
- +10 more
Sep 24, 2018
NSCLC Trial in Worldwide (Rociletinib, Pemetrexed or gemcitabine or paclitaxel or docetaxel)
Terminated
- Non-small Cell Lung Cancer
- Rociletinib
- Pemetrexed or gemcitabine or paclitaxel or docetaxel
-
Bakersfield, California
- +79 more
Jul 31, 2019
NSCLC Trial in Worldwide (Rociletinib Mono-Therapy, Erlotinib Mono-Therapy)
Terminated
- Non-Small Cell Lung Cancer
- Rociletinib Mono-Therapy
- Erlotinib Mono-Therapy
-
Birmingham, Alabama
- +73 more
Apr 29, 2019
Dermatitis, Atopic Trial in Worldwide (Dupilumab, Placebo (for Dupilumab))
Completed
- Dermatitis, Atopic
- Dupilumab
- Placebo (for Dupilumab)
-
Birmingham, Alabama
- +100 more
Nov 17, 2017
MDD Trial in United States (paroxetine CR)
Completed
- Major Depressive Disorder
- paroxetine CR
-
Birmingham, Alabama
- +70 more
Sep 8, 2017
Advanced Solid Tumors Trial in United Kingdom (PF-01367338, Carboplatin)
Completed
- Advanced Solid Tumors
-
Oxford, Oxfordshire, United Kingdom
- +5 more
Aug 7, 2017
NSCLC, NSCLC, Nonsmall Cell Lung Cancer Trial (Rociletinib, Biopsy, Blood draw)
Withdrawn
- Carcinoma, Non-Small-Cell Lung
- +2 more
- Rociletinib
- +2 more
- (no location specified)
May 16, 2016
T790M Mutation Positive 2nd Line STandard of cAre Registry
Withdrawn
- Non Small Cell Lung Cancer
-
Kentucky, Kentucky
- +49 more
Jul 6, 2015
Advanced Solid Tumor Trial in Amsterdam, Maastricht, Utrecht (CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of
Completed
- Advanced Solid Tumor
- CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)
- CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)
-
Amsterdam, Netherlands
- +2 more
Aug 13, 2014
Solid Tumor, Non-small-cell Lung Cancer, Lung Cancer Trial in United Kingdom, United States (CO-1.01 and Cisplatin)
Terminated
- Solid Tumor
- +2 more
- CO-1.01 and Cisplatin
-
Sarasota, Florida
- +3 more
Mar 8, 2014